# GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer

> **NCT07627191** · EARLY_PHASE1 · RECRUITING · sponsor: **University of Arizona** · enrollment: 30 (estimated)

## Conditions studied

- Pancreatic Cancer
- Colorectal Cancer
- Hepatocellular Carcinoma

## Interventions

- **DRUG:** GLP1-RA (semaglutide)

## Key facts

- **NCT ID:** NCT07627191
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-10-10
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07627191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07627191, "GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07627191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*